Did you know? Prevention and public health implications
Did you know that GLP-1 medications cannot be considered as a form of primary prevention, as they treat existing obesity rather than addressing its underlying determinants? Instead, they may contribute to secondary and tertiary prevention by reducing the risk of obesity-related disease, although their longer-term population health impact remains uncertain.
Read more in our report Exploring the public health and equalities implications of GLP-1 obesity medications.
Did you know? Prevention and public health implications
pdf | 1.68MB
Back to